Condition: Relapsed Malignant Solid Neoplasm · Sponsor: Aurigene Discovery Technologies Limited
An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced malignancies will be done to assess AUR107 safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose.
This description comes directly from the study's public registry record.
Suchit Kumbhare · +91 8104730078 · suchit_k@aurigene.com
Suresh Oduru · +91 9866225593 · suresh_o@aurigene.com
Always discuss trial participation with your own doctor first.
| HCG City Cancer Centre | Vijayawada, Andhra Pradesh, India | Not Yet Recruiting |
| Omega Hospital | Visakhapatnam, Andhra Pradesh, India | Recruiting |
| Post-Graduate Institute of Medical Education and Research(PGIMER) | Chandigarh, Chandigarh, India | Recruiting |
| Apollo Hospital International Limited | Ahmedabad, Gujarat, India | Recruiting |
| Universal Superspeciality Hospital | Surat, Gujarat, India | Recruiting |
| Unique Hospital Multispeciality and Research Institute | Surat, Gujarat, India | Recruiting |
| Kiran Hospital Multi Super Speciality Hospital & Research Centre | Surat, Gujarat, India | Recruiting |
| Pt.B.D Sharma PGIMS Rohtak | Rohtak, Haryana, India | Recruiting |
| Sri Shankara Cancer Hospital and Research Centre | Bangalore, Karnataka, India | Active Not Recruiting |
| Healthcare Global Enterprises Ltd | Bangalore, Karnataka, India | Recruiting |
| Cytecare Hospitals Pvt. Ltd | Bangalore, Karnataka, India | Recruiting |
| Vydehi Institute of Medical Sciences and Research Centre | Bangalore, Karnataka, India | Recruiting |
+ 25 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05865002